GSK secures first lung cancer approval as FDA clears Jideytro in quick payoff from Nuvalent deal

FDA approves Nuvalent's cancer drug, a week after GSK closed $10.6B buyout

The agency greenlit Jideytro for patients who have been previously treated with a ROS1 kinase inhibitor for ROS1-positive non-small cell lung cancer.